TrialThe journal of headache and pain2025

A phase 4, 24-week, open-label study to evaluate the safety and tolerability of once-daily dosing of 75 mg rimegepant for episodic migraine prevention.

Jeremias Antinew et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.